 |
11 Diseases |  |
5 Trials |
|
5 Trials |  |
28 News |  |
- | Opdivo (nivolumab) / Ono Pharma, BMS
Trial suspension: Nivolumab, Fluorouracil, and Interferon Alpha 2B for the Treatment of Unresectable Fibrolamellar Cancer (clinicaltrials.gov) - Feb 15, 2024
P1/2, N=15, Suspended, Sponsor: M.D. Anderson Cancer Center
Active, not recruiting --> Suspended
- | Opdivo (nivolumab) / Ono Pharma, BMS
Enrollment closed: Nivolumab, Fluorouracil, and Interferon Alpha 2B for the Treatment of Unresectable Fibrolamellar Cancer (clinicaltrials.gov) - Jan 3, 2024
P1/2, N=15, Active, not recruiting, Sponsor: M.D. Anderson Cancer Center
Active, not recruiting --> Suspended Recruiting --> Active, not recruiting
- ||| Novaferon (recombinant anti-tumor and anti-virus protein) / Genova
Phase classification, Enrollment change: A multicenter, randomized, open, controlled clinical study to evaluate the efficacy and safety of recombinant cytokine gene-derived protein injection in combination with standard therapy in patients with novel coronavirus infection (EUDRACT) - Dec 5, 2023
P4, N=480, Recruiting, Sponsor: The First Affiliated Hospital of Medical College of Zhejiang University; The First Affiliated Hospital of Medical College of Zhejiang University
Recruiting --> Active, not recruiting Phase classification: P3 --> P4 | N=320 --> 480
- | Novaferon (recombinant anti-tumor and anti-virus protein) / Genova
Journal, IO biomarker: Novaferon gene modification promotes NK92 cell anti-tumor activity. (Pubmed Central) - Jul 8, 2023
NK92-nova cells significantly inhibited HepG2 tumor growth in a xenograft model without systemic toxicity. Therefore, NK92-nova cells are a novel and safe strategy for cancer immunotherapy.
- | Opdivo (nivolumab) / Ono Pharma, BMS
Trial completion date, Trial primary completion date: Nivolumab, Fluorouracil, and Interferon Alpha 2B for the Treatment of Unresectable Fibrolamellar Cancer (clinicaltrials.gov) - Jun 22, 2023
P1/2, N=15, Recruiting, Sponsor: M.D. Anderson Cancer Center
Therefore, NK92-nova cells are a novel and safe strategy for cancer immunotherapy. Trial completion date: Jul 2023 --> Jul 2025 | Trial primary completion date: Jul 2023 --> Jul 2025
- ||| Novaferon (recombinant anti-tumor and anti-virus protein) / Genova
Retrospective data: If we take in account, pegIFN-III together trials, activ-2, and the initial early hong kong trials IFN-b1, novaferon trials, IFNa retrospective use from wang et al. The story looks like mab. (Twitter) - Oct 7, 2022
- | Novaferon (recombinant anti-tumor and anti-virus protein) / Genova
Preclinical, Journal: Novaferon Effectively Inhibits Ancestral SARS-CoV-2 and Omicron Variant in Vitro, 2022. (Pubmed Central) - Jul 13, 2022
The in vivo effects of Nova need to be further tested in animal models. And large-scale randomized double-blind clinical trials are needed to reveal its potentially clinical application.
- || lopinavir/ritonavir / Generic mfg.
Clinical, Review, Journal: Efficacy and safety of lopinavir-ritonavir in COVID-19: A systematic review of randomized controlled trials. (Pubmed Central) - Jun 9, 2021
And large-scale randomized double-blind clinical trials are needed to reveal its potentially clinical application. There is no benefit of the addition of lopinavir-ritonavir to the standard care in COVID-19 patients.
- || Novaferon (recombinant anti-tumor and anti-virus protein) / Genova
Clinical, Journal: Recent Biotechnological Approaches for Treatment of Novel COVID-19: From Bench to Clinical Trial. (Pubmed Central) - May 14, 2021
To date, an effective drug for reliable treatment of COVID-19 has not been registered or introduced to the international community. This review aims to provide recently presented techniques and protocols for efficient treatment of COVID-19 and investigate its morphology and treatment/prevention approaches, among which usage of antiviral drugs, anti-malarial drugs, corticosteroids, and traditional medicines, biotechnological drugs (e.g., combination of HCQ and azithromycin, remdesivir, interferons, novaferon, interferon-alpha-1b, thymosin, and monoclonal antibodies) can be mentioned.
- ||| Novaferon (recombinant anti-tumor and anti-virus protein) / Zhejiang University, Second Xiangya Hospital of Central South University, Emcure, interferon beta inhalation (SNG001) / Synairgen
Observational data, P2 data, Retrospective data: As non longitudinal study, no answer. Probably a combination of both. Local and early intevention was successful in golden hamster model, in retrospective studies and in phase 2 with IFNk, novaferon and SNG001. (Twitter) - Mar 11, 2021
- | Opdivo (nivolumab) / Ono Pharma, BMS
Enrollment open, Trial completion date, Trial initiation date, Trial primary completion date: Nivolumab, Fluorouracil, and Interferon Alpha 2B for the Treatment of Unresectable Fibrolamellar Cancer (clinicaltrials.gov) - Feb 25, 2021
P1/2, N=15, Recruiting, Sponsor: M.D. Anderson Cancer Center
This review aims to provide recently presented techniques and protocols for efficient treatment of COVID-19 and investigate its morphology and treatment/prevention approaches, among which usage of antiviral drugs, anti-malarial drugs, corticosteroids, and traditional medicines, biotechnological drugs (e.g., combination of HCQ and azithromycin, remdesivir, interferons, novaferon, interferon-alpha-1b, thymosin, and monoclonal antibodies) can be mentioned. Not yet recruiting --> Recruiting | Trial completion date: Jul 2021 --> Jul 2023 | Initiation date: Sep 2020 --> Jan 2021 | Trial primary completion date: Jul 2021 --> Jul 2023
- || Novaferon (recombinant anti-tumor and anti-virus protein) / Zhejiang University, Second Xiangya Hospital of Central South University, Emcure
Clinical, Journal: Reply to "Novaferon, Treatment in COVID-19 Patients". (Pubmed Central) - Feb 12, 2021
Not yet recruiting --> Recruiting | Trial completion date: Jul 2021 --> Jul 2023 | Initiation date: Sep 2020 --> Jan 2021 | Trial primary completion date: Jul 2021 --> Jul 2023 No abstract available
- || Novaferon (recombinant anti-tumor and anti-virus protein) / Zhejiang University, Second Xiangya Hospital of Central South University, Emcure
Clinical, Journal: Novaferon, Treatment in COVID-19 Patients. (Pubmed Central) - Feb 12, 2021
No abstract available No abstract available
- | lopinavir/ritonavir / Generic mfg.
Journal, HEOR: Comparative Effectiveness of Lopinavir/Ritonavir-Based Regimens in COVID-19. (Pubmed Central) - Jan 15, 2021
In conclusion, the combination of LPV/r and Novaferon may have better efficacy against COVID-19. However, adding IFN based on LPV/r+Novaferon or adding Arbidol based on LPV/r+IFN may not improve the efficacy.
- || Novaferon (recombinant anti-tumor and anti-virus protein) / Zhejiang University, Second Xiangya Hospital of Central South University, Emcure
Clinical, Journal: SARS-CoV-2 Clearance in COVID-19 Patients with Novaferon Treatment: A Randomized, Open-label, Parallel Group Trial. (Pubmed Central) - Oct 27, 2020
Novaferon exhibited anti-SARS-CoV-2 effects in vitro and in COVID-19 patients. These data justify further evaluation of Novaferon.
- | Novaferon (recombinant anti-tumor and anti-virus protein) / Zhejiang University, Second Xiangya Hospital of Central South University, Emcure
Journal: Determination of Antioxidant 264 in the Butyl Rubber Stopper and the Compatibility with Recombinant Potent Antitumor and Antivirus Protein Injection. (Pubmed Central) - Sep 25, 2020
The results indicated that antioxidant 264 was not detected in Novaferon after the accelerated test and three months of long-term test. The established validated method in this study can be used for the determination of antioxidant 264 in the rubber stopper, and the brominated butyl rubber stopper has good compatibility with Novaferon.
- || lopinavir/ritonavir / Generic mfg.
Clinical, Retrospective data, Journal: Clinical characteristics and drug therapies in patients with the common-type coronavirus disease 2019 in Hunan, China. (Pubmed Central) - Jun 14, 2020
Conclusion As of February 10, 2020, the symptoms of COVID-19 patients in Hunan province were relatively mild comparing to patients in Wuhan, the epicenter. We observed some treatment benefits with interferon-α2b and corticosteroid therapies but not with novaferon and antibiotic treatment in our study population.
- || lopinavir/ritonavir / Generic mfg.
Clinical, Journal: Clinical characteristics and drug therapies in patients with the common-type coronavirus disease 2019 in Hunan, China. (Pubmed Central) - May 16, 2020
Conclusion As of February 10, 2020, the symptoms of COVID-19 patients in Hunan province were relatively mild comparing to patients in Wuhan, the epicenter. We observed some treatment benefits with interferon-α2b and corticosteroid therapies but not with novaferon and antibiotic treatment in our study population.
- | Opdivo (nivolumab) / Ono Pharma, BMS
New P1/2 trial: Nivolumab, Fluorouracil, and Interferon Alpha 2B for the Treatment of Unresectable Fibrolamellar Cancer (clinicaltrials.gov) - May 7, 2020
P1/2, N=15, Not yet recruiting, Sponsor: M.D. Anderson Cancer Center
- capecitabine / Generic mfg.
Trial primary completion date, Metastases: Recombinant Anti-tumor and Anti-virus Protein for Injection Plus Xeloda in Treatment of Metastatic Colorectal Cancer (clinicaltrials.gov) - Jan 17, 2016
P2, N=30, Recruiting, Sponsor: The Affiliated Hospital of the Chinese Academy of Military Medical Sciences
We observed some treatment benefits with interferon-α2b and corticosteroid therapies but not with novaferon and antibiotic treatment in our study population. Trial primary completion date: Nov 2015 --> Nov 2016
- |||| Novaferon (recombinant anti-tumor and anti-virus protein) / Genova
Trial completion, Phase classification, Enrollment change, Metastases: Recombinant Anti-tumor and Anti-virus Protein for Injection in Treatment of Metastatic Colorectal Cancer (clinicaltrials.gov) - Jan 7, 2016
P2, N=108, Completed, Sponsor: The Affiliated Hospital of the Chinese Academy of Military Medical Sciences
Trial primary completion date: Nov 2015 --> Nov 2016 Active, not recruiting --> Completed | Phase classification: P2/3 --> P2 | N=805 --> 108
- Novaferon (recombinant anti-tumor and anti-virus protein) / Genova
Enrollment open, Metastases: Recombinant Anti-tumor and Anti-virus Protein for Injection to Treat Advanced Neuroendocrine Tumors (clinicaltrials.gov) - Aug 26, 2015
P2, N=20, Recruiting, Sponsor: The Affiliated Hospital of the Chinese Academy of Military Medical Sciences
Active, not recruiting --> Completed | Phase classification: P2/3 --> P2 | N=805 --> 108 Not yet recruiting --> Recruiting
- Novaferon (recombinant anti-tumor and anti-virus protein) / Genova
New P2 trial, Metastases: Recombinant Anti-tumor and Anti-virus Protein for Injection to Treat Advanced Neuroendocrine Tumors (clinicaltrials.gov) - May 28, 2015
P2, N=20, Not yet recruiting, Sponsor: The Affiliated Hospital of the Chinese Academy of Military Medical Sciences
- |||||||||| Novaferon (recombinant anti-tumor and anti-virus protein) / Genova
New P2/3 trial, Metastases: Recombinant Anti-tumor and Anti-virus Protein for Injection in Treatment of Metastatic Colorectal Cancer (clinicaltrials.gov) - Jan 29, 2015
P2/3, N=105, Recruiting, Sponsor: Beijing Genova Biotech Company, Ltd.
- capecitabine / Generic mfg.
New P2 trial, Metastases: Recombinant Anti-tumor and Anti-virus Protein for Injection Plus Xeloda in Treatment of Metastatic Colorectal Cancer (clinicaltrials.gov) - Feb 19, 2014
P2, N=30, Recruiting, Sponsor: The Affiliated Hospital of the Chinese Academy of Military Medical Sciences
- ||||| Novaferon (recombinant anti-tumor and anti-virus protein) / Genova
Enrollment closed, Metastases: Recombinant Anti-tumor and Anti-virus Protein for Injection in Treatment of Metastatic Colorectal Cancer (clinicaltrials.gov) - Dec 25, 2013
P2/3, N=805, Active, not recruiting, Sponsor: The Affiliated Hospital of the Chinese Academy of Military Medical Sciences
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting